ArticleFunctional & integrative genomics2026
Tumor-derived exosomes carry LCN2 to block Nedd4-1-mediated SR-BI ubiquitination, inducing M2 macrophage polarization and promoting hepatocellular carcinoma growth.
Article in Functional & integrative genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Advances in understanding exosome-mediated regulation of macrophage function.Frontiers in immunology · 2026Review
- Targeting lipocalin-2 in atherosclerosis: biological functions, pathogenic mechanisms, and therapeutic potential.Frontiers in cardiovascular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is a highly prevalent and lethal malignancy with complex pathogenesis and limited treatment options. Exosomes play crucial roles in HCC development and progression. This study aimed to comprehensively investigate the differential expression and functional roles of lipocalin-2 (LCN2) in HCC exosomes. Bioinformatics analysis of the GSE199509 dataset identified 4518 differential expression genes (DEGs) between HCC patient-derived exosomes and normal controls, with LCN2 being highly expressed in HCC exosomes. In vitro experiments showed that LCN2 was significantly enriched in exosomes from HCC cell lines (SMMC-7721 and HepG2). HCC-derived exosomes induced M2 macrophage polarization, which promoted HCC cell migration, invasion, and proliferation. Knockdown of LCN2 attenuated HCC exosome-induced M2 macrophage polarization and reduced the pro-tumor effects on HCC cells. Mechanistically, LCN2 inhibited Nedd4-1-mediated ubiquitination and degradation of SR-BI in a Nedd4-1-dependent manner. SR-BI overexpression reversed the effects of LCN2 knockdown on macrophage polarization and HCC cell proliferation. In vivo mouse models demonstrated that LCN2 knockdown inhibited tumor growth in wild-type mice but not in SR-BI knockout mice. These findings suggest that LCN2 plays a pivotal role in HCC progression through modulating macrophage polarization and interacting with SR-BI. Targeting the LCN2-SR-BI axis may represent a novel therapeutic strategy for HCC. Additionally, exosomal LCN2 could be a potential biomarker for HCC diagnosis and prognosis. However, further pre-clinical and clinical studies are needed to validate these findings.
Indexed as
Identifiers
41493511What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.